Novo Nordisk A/S (NYSE:NVO) Stock Holdings Lessened by Everett Harris & Co. CA

Everett Harris & Co. CA cut its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 0.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,408,022 shares of the company's stock after selling 45,067 shares during the period. Novo Nordisk A/S comprises approximately 5.7% of Everett Harris & Co. CA's investment portfolio, making the stock its 5th largest holding. Everett Harris & Co. CA owned 0.14% of Novo Nordisk A/S worth $444,973,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of NVO. Truepoint Inc. bought a new position in Novo Nordisk A/S in the 1st quarter valued at $413,000. Brookmont Capital Management boosted its holdings in shares of Novo Nordisk A/S by 30.1% in the 1st quarter. Brookmont Capital Management now owns 57,632 shares of the company's stock worth $4,002,000 after buying an additional 13,323 shares during the last quarter. Bristlecone Advisors LLC increased its holdings in Novo Nordisk A/S by 102.3% during the first quarter. Bristlecone Advisors LLC now owns 24,869 shares of the company's stock worth $1,727,000 after buying an additional 12,576 shares during the last quarter. Savvy Advisors Inc. raised its position in Novo Nordisk A/S by 68.7% in the first quarter. Savvy Advisors Inc. now owns 12,014 shares of the company's stock worth $834,000 after acquiring an additional 4,891 shares during the period. Finally, Hirtle Callaghan & Co LLC bought a new position in shares of Novo Nordisk A/S during the 1st quarter valued at approximately $1,289,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of research reports. Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Hsbc Global Res lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. UBS Group downgraded shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a report on Tuesday. BMO Capital Markets reissued a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Finally, HSBC lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target for the company. in a report on Thursday, July 31st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and an average target price of $93.67.

Novo Nordisk A/S Trading Up 7.5%

Novo Nordisk A/S stock opened at $48.76 on Friday. The stock has a market cap of $217.73 billion, a P/E ratio of 13.40, a PEG ratio of 1.37 and a beta of 0.63. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $139.74. The firm's fifty day moving average price is $67.55 and its 200-day moving average price is $71.81. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 84.92%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be given a dividend of $0.4119 per share. The ex-dividend date is Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is 45.05%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.